By SmashMeals Editorial — 2026-09-03 — Health & Nutrition
The short answer
Teva reported that one dose of investigational anti-IL-15 antibody TEV-408 reduced gluten-induced intestinal damage versus placebo in a randomized Phase 2a study of 50 adults completing a supervised gluten challenge. These are early topline results, not full peer-reviewed evidence or an approval, and they do not replace today's gluten-free diet.
Key facts
- Randomized, placebo-controlled Phase 2a study in 50 adults.
- Participants completed a six-week medically supervised gluten challenge.
- The company reported the primary endpoint was met at week eight.
- TEV-408 is investigational and not approved for celiac disease.
KINGSPORT, Tenn., Sept. 3, 2026 — Teva reported positive topline results from a Phase 2a trial of TEV-408, an investigational antibody designed to block interleukin-15. The Celiac Disease Foundation's account says the randomized, placebo-controlled study included 50 adults with celiac disease.
SmashMeals is a prepared-food company, not a medical provider. Food and nutrition decisions involving a health condition or medication should be individualized with a clinician or registered dietitian.
What the trial tested
Participants received a single dose of TEV-408 or placebo and then completed a six-week gluten challenge under medical supervision. At week eight, Teva reported less gluten-induced intestinal damage in the treatment group, meeting the study's primary endpoint. The Foundation also reports lower inflammation and gastrointestinal symptom scores.
The trial-results page from Teva is a company source. “Positive topline” means selected high-level results were announced; it is not the same as a complete peer-reviewed paper with all data available for independent assessment.
Why IL-15 is being studied
Interleukin-15 is involved in the immune response associated with gluten exposure in celiac disease. TEV-408 is designed to block that signal. A biologically plausible mechanism and a met primary endpoint are reasons for continued study—not proof that the drug will survive larger trials, receive approval or work the same way in routine care.
The limits are as important as the headline
This was a small, early-phase trial with 50 adults, one dose and a controlled challenge. The available public information is topline reporting. Larger and longer studies are needed to evaluate safety, durability, dosing and who may benefit.
Marilyn Geller, CEO of the Celiac Disease Foundation, described the result as encouraging while the Foundation's article explicitly notes that TEV-408 is investigational and not approved. Eric Hughes, MD, PhD, commented for Teva in his company role; his statement should be read as the sponsor's interpretation, not independent validation.
Why the gluten-free diet still matters
The NIDDK continues to describe a gluten-free diet as the way people with celiac disease manage the condition. Nothing in a Phase 2a announcement changes that current standard.
People should not conduct their own gluten challenge or alter a medically indicated diet because of a research headline. Those decisions belong with a clinician.
What this means for food companies
Food companies should not use an investigational drug story to relax preparation standards or imply that customers can tolerate gluten. SmashMeals operates a dedicated gluten-free kitchen in Kingsport and keeps the commercial promise narrow: prepared food, current labels and a production environment without gluten-containing ingredients.
Commentary, not medical advice
The SmashMeals perspective
A potential future therapy would not make accurate food information or careful preparation irrelevant. Today, SmashMeals' role is straightforward: prepare food in a dedicated gluten-free kitchen and publish meal information customers can review. We do not treat celiac disease, recommend medication or suggest that food replaces clinical care.
Frequently asked questions
Is TEV-408 approved for celiac disease?
No. TEV-408 is investigational. The September announcement described early Phase 2a topline results.
Can people with celiac disease stop following a gluten-free diet?
No conclusion like that follows from this trial. Current guidance still centers on a gluten-free diet, individualized with a clinician or dietitian.
Did SmashMeals participate in or sponsor the trial?
No. SmashMeals had no role in the study and is not affiliated with Teva or the Celiac Disease Foundation.
Sources & experts referenced
Sources are included for verification. No expert listed here endorses SmashMeals.
- Teva announces positive Phase 2a results for investigational celiac treatment — Celiac Disease Foundation
Expert referenced: Marilyn Geller, CEO, Celiac Disease Foundation
Why it matters: Summarizes the study and clearly states that the treatment remains investigational and needs more research. - TEV-53408IMM20042 clinical trial results — Teva Pharmaceutical Industries
Expert referenced: Eric Hughes, MD, PhD — Teva executive and chief medical officer
Why it matters: Company source for the protocol and reported results; company statements are not independent validation. - Eating, Diet, & Nutrition for Celiac Disease — National Institute of Diabetes and Digestive and Kidney Diseases
Why it matters: Describes the gluten-free diet used to manage celiac disease today.